Pay in 4 interest-free payments of $5.98 Learn more
Ships within 48 hours · Estimated delivery Oct 9 - Oct 14
A randomized controlled trial of semaglutide in 320 persons with NASH (with or without T2D) showed that subcutaneous semaglutide led to a significantly higher proportion of persons with the resolution of NASH than the placebo group, with no statistically significant difference in the improvement of fibrosis stage [12]
(September 2005)
Cost is also significantly higher , with grey market retatrutide typically running 2-3x the price of compounded tirzepatide
The scale goes down, but you look softer, not leaner
Eli Lilly is close to launching the strongest weight-loss drug ever
US$ 26.69
US$ 27.58
US$ 29.49
